Related Experiment Videos
[Low diuretic dosage in a beta blocker-diuretic combination]
Insights
Cardiotensin, a combination of bupranolol, bemetizide, and triamterene, effectively lowered blood pressure in most hypertensive patients within two weeks. The medication demonstrated good tolerability and did not significantly affect serum potassium or glucose levels.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Clinical Therapeutics
Background:
- Arterial hypertension is a significant global health concern requiring effective management.
- Combination therapies are often employed to achieve better blood pressure control.
Purpose of the Study:
- To evaluate the efficacy and tolerability of Cardiotensin in treating outpatients with arterial hypertension.
- To assess the impact of Cardiotensin on blood pressure, heart rate response to stress, and key biochemical parameters.
Main Methods:
- A prospective study involving 30 outpatients with arterial hypertension.
- An eight-week treatment period with a daily dose of Cardiotensin (100mg bupranolol, 10mg bemetizide, 20mg triamterene) after a one-week placebo washout.
- Blood pressure monitoring, ergometer stress testing, and analysis of serum potassium, uric acid, creatinine, and glucose levels.
Main Results:
- Twenty-six out of 30 patients achieved normal blood pressure levels within two weeks.
- Significant reductions in blood pressure and heart rate elevations during ergometer stress testing were observed.
- No significant changes in serum potassium, uric acid, creatinine, or glucose concentrations were noted.
- Cardiotensin demonstrated good overall tolerability.
Conclusions:
- Cardiotensin is an effective and well-tolerated treatment for arterial hypertension.
- The combination therapy normalizes blood pressure in a majority of patients and mitigates abnormal cardiovascular responses to stress.
- It offers a favorable biochemical profile without adverse effects on electrolytes or metabolic markers.
Abstract:
Thirty outpatients with arterial hypertension were treated for eight weeks with a daily dose of one tablet of Cardiotensin, taken after breakfast. The compound contains 100mg bupranolol, 10mg bemetizide and 20mg triamterene. Drug therapy was preceded by a one-week placebo washout period. Within two weeks of treatment, systolic and diastolic blood pressure had reverted to normal in 26 of the patients. At the end of the observation period, 4 patients still had diastolic pressure values of more than 100 mm Hg. Ergometer stress testing revealed clear-cut diminution of blood pressure and heart rate elevations following the medication. Serum potassium levels were not influenced by the drug. Under the mentioned dose regimen there were no changes in serum uric acid, creatinine, and glucose concentrations. Tolerability was generally good.